Oak Thistle LLC Sells 2,363 Shares of McKesson Corporation $MCK

Key Points

• Oak Thistle LLC cut its stake in McKesson by 81.8% in Q4, selling 2,363 shares and leaving the firm with 527 shares valued at about $432,000.
• Insiders sold stock recently — EVP Leann B. Smith sold 190 shares and EVP Michele Lau sold 2,725 shares, and insiders disposed of 3,592 shares worth $3,518,555 in the quarter while insiders now own just 0.08% of the company.
• McKesson beat quarterly expectations with $9.34 EPS and $106.16 billion in revenue, set FY2026 guidance of $38.80–$39.20 EPS, and carries a consensus analyst rating of “Moderate Buy” with an average target of $970.93.

Oak Thistle LLC lowered its stake in McKesson Corporation (NYSE:MCK - Free Report) by 81.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 527 shares of the company's stock after selling 2,363 shares during the quarter. Oak Thistle LLC's holdings in McKesson were worth $432,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Sivik Global Healthcare LLC lifted its holdings in shares of McKesson by 28.6% in the fourth quarter. Sivik Global Healthcare LLC now owns 9,000 shares of the company's stock worth $7,383,000 after acquiring an additional 2,000 shares during the last quarter. Greenleaf Trust increased its stake in shares of McKesson by 3.5% in the fourth quarter. Greenleaf Trust now owns 7,257 shares of the company's stock valued at $5,953,000 after buying an additional 245 shares during the period. Petra Financial Advisors Inc. increased its stake in shares of McKesson by 1.0% in the fourth quarter. Petra Financial Advisors Inc. now owns 1,477 shares of the company's stock valued at $1,212,000 after buying an additional 15 shares during the period. Azzad Asset Management Inc. ADV acquired a new position in shares of McKesson in the fourth quarter valued at approximately $358,000. Finally, Groesbeck Investment Management Corp NJ acquired a new position in shares of McKesson in the fourth quarter valued at approximately $285,000. Institutional investors own 85.07% of the company's stock.

Insider Buying and Selling at McKesson

In related news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president owned 2,989 shares of the company's stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the sale, the executive vice president directly owned 3,247 shares of the company's stock, valued at approximately $3,214,530. The trade was a 45.63% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,592 shares of company stock worth $3,518,555. 0.08% of the stock is owned by company insiders.

McKesson Stock Down 0.8%

Shares of MCK stock opened at $866.02 on Friday. The company has a market cap of $106.08 billion, a price-to-earnings ratio of 24.91, a price-to-earnings-growth ratio of 1.25 and a beta of 0.42. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The firm has a 50 day moving average of $916.22 and a 200-day moving average of $851.24.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company's quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 1st. Investors of record on Monday, March 2nd were given a $0.82 dividend. The ex-dividend date of this dividend was Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson's dividend payout ratio (DPR) is presently 9.43%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on MCK shares. Leerink Partners reaffirmed an "outperform" rating and issued a $1,085.00 price objective on shares of McKesson in a research note on Thursday, March 5th. JPMorgan Chase & Co. upped their price objective on McKesson from $983.00 to $1,107.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Bank of America lowered their price objective on McKesson from $1,040.00 to $1,000.00 and set a "buy" rating for the company in a research note on Monday, April 6th. Raymond James Financial set a $970.00 price objective on McKesson in a research note on Thursday, March 5th. Finally, Weiss Ratings downgraded McKesson from a "buy (a-)" rating to a "buy (b+)" rating in a research note on Thursday, February 5th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $970.93.

McKesson Company Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.